Grace Gene Therapy

Company Overview

Snapshot

Founded in November 2024 by Fadi Assaf, Grace Gene Therapy operates with 1–10 employees. The company has secured funding across one round from NGT HealthCare II, focusing on developing a gene therapy treatment for Parkinson’s disease.

Business overview

Grace Gene Therapy is pioneering a gene therapy treatment for Parkinson’s disease, utilizing a first-in-class chemogenetic agent. Its core technology involves DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) to selectively target and adjust neural networks in the basal ganglia, offering a unique approach compared to traditional dopaminergic system-based treatments. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare and life sciences markets.

Company Intelligence Q&A

What is Grace Gene Therapy's primary focus?

Grace Gene Therapy is focused on developing a revolutionary gene therapy treatment for Parkinson’s disease, utilizing a first-in-class chemogenetic agent.

When was Grace Gene Therapy founded?

Grace Gene Therapy was founded in November 2024.

Who founded Grace Gene Therapy?

Grace Gene Therapy was co-founded by Fadi Assaf.

What is the core technology behind Grace Gene Therapy's treatment?

The core technology involves using DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) to precisely target and modulate specific regions of the brain's neural network, particularly the basal ganglia, to address Parkinson's disease.

Has Grace Gene Therapy received any funding?

In November 2024, Grace Gene Therapy secured funding in a Pre-Seed round from NGT HealthCare II.